Discounted Cash Flow (DCF) Analysis Unlevered

TScan Therapeutics, Inc. (TCRX)

$3.29

-0.03 (-0.90%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 3.29 | undervalue

Operating Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
Revenue (%)
EBITDA --------
EBITDA (%)
EBIT --------
EBIT (%)
Depreciation --------
Depreciation (%)

Balance Sheet Data

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash --------
Total Cash (%)
Account Receivables --------
Account Receivables (%)
Inventories --------
Inventories (%)
Accounts Payable --------
Accounts Payable (%)
Capital Expenditure --------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 3.29
Beta 0.000
Diluted Shares Outstanding 11.66
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 2.842
Total Debt 6.04
Total Equity 38.37
Total Capital 44.41
Debt Weighting 13.61
Equity Weighting 86.39
Wacc

Build Up Free Cash

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue --------
EBITDA --------
EBIT --------
Tax Rate 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
EBIAT --------
Depreciation --------
Accounts Receivable --------
Inventories --------
Accounts Payable --------
Capital Expenditure -1.25-4.24-9.94-----
UFCF --------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -155.36
Equity Value -
Shares Outstanding 11.66
Equity Value Per Share -